227 related articles for article (PubMed ID: 33507344)
1. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
[TBL] [Abstract][Full Text] [Related]
3. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
4. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
5. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways.
Johnson BM; Uchimura T; Gallovic MD; Thamilarasan M; Chou WC; Gibson SA; Deng M; Tam JW; Batty CJ; Williams J; Matsushima GK; Bachelder EM; Ainslie KM; Markovic-Plese S; Ting JP
J Immunol; 2021 May; 206(9):2015-2028. PubMed ID: 33820855
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response.
Marcus A; Mao AJ; Lensink-Vasan M; Wang L; Vance RE; Raulet DH
Immunity; 2018 Oct; 49(4):754-763.e4. PubMed ID: 30332631
[TBL] [Abstract][Full Text] [Related]
7. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
8. Activation of STING signaling accelerates skin wound healing.
Mizutani Y; Kanbe A; Ito H; Seishima M
J Dermatol Sci; 2020 Jan; 97(1):21-29. PubMed ID: 31813660
[TBL] [Abstract][Full Text] [Related]
9. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
[TBL] [Abstract][Full Text] [Related]
10. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
[TBL] [Abstract][Full Text] [Related]
11. Cyclic dinucleotides modulate induced type I IFN responses in innate immune cells by degradation of STING.
Rueckert C; Rand U; Roy U; Kasmapour B; Strowig T; Guzmán CA
FASEB J; 2017 Jul; 31(7):3107-3115. PubMed ID: 28396343
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function.
Imanishi T; Unno M; Kobayashi W; Yoneda N; Matsuda S; Ikeda K; Hoshii T; Hirao A; Miyake K; Barber GN; Arita M; Ishii KJ; Akira S; Saito T
Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30683688
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
14. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections.
Yum S; Li M; Fang Y; Chen ZJ
Proc Natl Acad Sci U S A; 2021 Apr; 118(14):. PubMed ID: 33785602
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma.
Harabuchi S; Kosaka A; Yajima Y; Nagata M; Hayashi R; Kumai T; Ohara K; Nagato T; Oikawa K; Ohara M; Harabuchi Y; Ohkuri T; Kobayashi H
Biochem Biophys Res Commun; 2020 Feb; 522(2):408-414. PubMed ID: 31771883
[TBL] [Abstract][Full Text] [Related]
16. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
[TBL] [Abstract][Full Text] [Related]
17. cGAS/cGAMP/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity.
Mekers VE; Kho VM; Ansems M; Adema GJ
Radiother Oncol; 2022 Sep; 174():158-167. PubMed ID: 35870728
[TBL] [Abstract][Full Text] [Related]
18. CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T
Benoit-Lizon I; Jacquin E; Rivera Vargas T; Richard C; Roussey A; Dal Zuffo L; Martin T; Melis A; Vinokurova D; Shahoei SH; Baeza Garcia A; Pignol C; Giorgiutti S; Carapito R; Boidot R; Végran F; Flavell RA; Ryffel B; Nelson ER; Soulas-Sprauel P; Lawrence T; Apetoh L
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091453
[TBL] [Abstract][Full Text] [Related]
19. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
20. Microparticle Delivery of a STING Agonist Enables Indirect Activation of NK Cells by Antigen-Presenting Cells.
Watkins-Schulz R; Batty CJ; Stiepel RT; Schmidt ME; Sandor AM; Chou WC; Ainslie KM; Bachelder EM; Ting JP
Mol Pharm; 2022 Sep; 19(9):3125-3138. PubMed ID: 35913984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
